Six-year (yr) follow-up of patients (pts) with imatinib-resistant or -intolerant chronic-phase chronic myeloid leukemia (CML-CP) receiving dasatinib.
Neil P. Shah
Consultant or Advisory Role - ARIAD; Bristol-Myers Squibb; Novartis
Hagop Kantarjian
Consultant or Advisory Role - Novartis
Research Funding - Bristol-Myers Squibb; Novartis; Pfizer
Dong-Wook Kim
Consultant or Advisory Role - Bristol-Myers Squibb (U); IL-Yang Pharm (U); Novartis (U); Pfizer (U)
Honoraria - Bristol-Myers Squibb; Novartis
Research Funding - Bristol-Myers Squibb; Novartis
Andreas Hochhaus
Research Funding - Bristol-Myers Squibb; Novartis
Giuseppe Saglio
Consultant or Advisory Role - Bristol-Myers Squibb; Novartis
Honoraria - Bristol-Myers Squibb; Novartis
Francois Guilhot
Consultant or Advisory Role - Bristol-Myers Squibb
Charles Alan Schiffer
Consultant or Advisory Role - Ambit BioSciences; ARIAD; Bristol-Myers Squibb; Genzyme; Novartis; Pfizer
Research Funding - Ambit BioSciences; ARIAD; Bristol-Myers Squibb; Celgene; Novartis
Juan Luis Steegmann
Consultant or Advisory Role - Amgen; Bristol-Myers Squibb; Novartis
Research Funding - Amgen; Bristol-Myers Squibb; Novartis
Hesham Mohamed
Employment or Leadership Position - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb
David Dejardin
Employment or Leadership Position - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb
Diane I. Healey
Employment or Leadership Position - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb
Jorge E. Cortes
Consultant or Advisory Role - Bristol-Myers Squibb; Novartis
Research Funding - ARIAD; Bristol-Myers Squibb; ChemGenex; Deciphera; Novartis; Pfizer